Literature DB >> 20436524

Pretransplant serum ferritin and C-reactive protein as predictive factors for early bacterial infection after allogeneic hematopoietic cell transplantation.

J Kanda1, C Mizumoto, T Ichinohe, H Kawabata, T Saito, K Yamashita, T Kondo, S Takakura, S Ichiyama, T Uchiyama, T Ishikawa.   

Abstract

Although fluoroquinolones or other antibiotics are commonly used to prevent bacterial infections after hematopoietic cell transplantation (HCT), because of the growing presence of multidrug-resistant microorganisms, it is important to identify patients who are more likely to benefit from antibacterial prophylaxis. To evaluate risk factors for early bacterial infection after allogeneic HCT, we retrospectively analyzed clinical data for 112 consecutive adult patients with hematological malignancies who received transplants without any antibacterial prophylaxis. The cumulative incidence of bacterial infection at 30 days after transplantation was 16%. Among various pre-transplant factors, only high serum ferritin (>700 ng/mL, 47 patients) and high C-reactive protein (CRP) (>0.3 mg/dL, 28 patients) levels were significantly associated with the development of bacterial infection in a multivariate analysis (hazard ratio (95% confidence interval): ferritin, 4.00 (1.32-12.17); CRP, 3.64 (1.44-9.20)). In addition, septic shock and sepsis with organ failure were exclusively observed in patients who had high ferritin and/or high CRP levels. These results suggest that pretransplant serum ferritin and CRP levels can be useful markers for predicting the risk of early bacterial infection after allogeneic HCT. It may be prudent to limit antibacterial prophylaxis to patients with predefined risk factors to ensure the safety of HCT with the use of fewer antibiotics.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20436524     DOI: 10.1038/bmt.2010.108

Source DB:  PubMed          Journal:  Bone Marrow Transplant        ISSN: 0268-3369            Impact factor:   5.483


  19 in total

1.  Development of a simplified multivariable model to predict neutropenic complications in cancer patients undergoing chemotherapy.

Authors:  Abolfazl Razzaghdoust; Bahram Mofid; Maryam Moghadam
Journal:  Support Care Cancer       Date:  2018-05-07       Impact factor: 3.603

2.  Risk factor for death in hematopoietic stem cell transplantation: are biomarkers useful to foresee the prognosis in this population of patients?

Authors:  K S R Massaro; R Macedo; B S de Castro; F Dulley; M S Oliveira; M A S Yasuda; A S Levin; S F Costa
Journal:  Infection       Date:  2014-09-30       Impact factor: 3.553

3.  Clinical significance of pretransplant serum ferritin on the outcome of allogeneic hematopoietic SCT: a prospective cohort study by the Kanto Study Group for Cell Therapy.

Authors:  M Tanaka; H Kanamori; K Matsumoto; T Tachibana; A Numata; K Ohashi; T Kobayashi; C Nakaseko; Y Kanda; E Yamazaki; S Fujisawa; J Ooi; T Sakura; N Aotsuka; M Onoda; S Machida; J Kato; K Usuki; R Watanabe; J Taguchi; S Yano; T Saito; S Takahashi; H Sakamaki; S Okamoto
Journal:  Bone Marrow Transplant       Date:  2015-03-02       Impact factor: 5.483

4.  Association between pretransplant iron overload determined by bone marrow pathological analysis and bacterial infection.

Authors:  A Ohmoto; S Fuji; A Miyagi-Maeshima; S-W Kim; K Tajima; T Tanaka; K Okinaka; S Kurosawa; Y Inamoto; H Taniguchi; T Fukuda
Journal:  Bone Marrow Transplant       Date:  2017-05-15       Impact factor: 5.483

5.  Age-adjusted recipient pretransplantation telomere length and treatment-related mortality after hematopoietic stem cell transplantation.

Authors:  Régis Peffault de Latour; Rodrigo T Calado; Marc Busson; Jeffrey Abrams; Nadir Adoui; Marie Robin; Jérôme Larghero; Nathalie Dhedin; Alienor Xhaard; Emmanuel Clave; Dominique Charron; Antoine Toubert; Pascale Loiseau; Gérard Socié; Neal S Young
Journal:  Blood       Date:  2012-09-04       Impact factor: 22.113

6.  Does iron overload really matter in stem cell transplantation?

Authors:  Philippe Armand; Marie-Michele Sainvil; Haesook T Kim; Joanna Rhodes; Corey Cutler; Vincent T Ho; John Koreth; Edwin P Alyea; Ellis J Neufeld; Raymond Y Kwong; Robert J Soiffer; Joseph H Antin
Journal:  Am J Hematol       Date:  2012-04-04       Impact factor: 10.047

7.  Design and Validation of an Augmented Hematopoietic Cell Transplantation-Comorbidity Index Comprising Pretransplant Ferritin, Albumin, and Platelet Count for Prediction of Outcomes after Allogeneic Transplantation.

Authors:  Jennifer E Vaughn; Barry E Storer; Philippe Armand; Roberto Raimondi; Christopher Gibson; Alessandro Rambaldi; Fabio Ciceri; Rosi Oneto; Benedetto Bruno; Paul J Martin; Brenda M Sandmaier; Rainer Storb; Mohamed L Sorror
Journal:  Biol Blood Marrow Transplant       Date:  2015-04-07       Impact factor: 5.742

8.  Differing impacts of pretransplant serum ferritin and C-reactive protein levels on the incidence of chronic graft-versus-host disease after allogeneic hematopoietic stem cell transplantation.

Authors:  Soichiro Sakamoto; Hiroshi Kawabata; Junya Kanda; Tatsuki Uchiyama; Chisaki Mizumoto; Tadakazu Kondo; Kouhei Yamashita; Tatsuo Ichinohe; Takayuki Ishikawa; Norimitsu Kadowaki; Akifumi Takaori-Kondo
Journal:  Int J Hematol       Date:  2012-12-07       Impact factor: 2.490

9.  Phase IV open-label study of the efficacy and safety of deferasirox after allogeneic stem cell transplantation.

Authors:  Carlos Vallejo; Montserrat Batlle; Lourdes Vázquez; Carlos Solano; Antonia Sampol; Rafael Duarte; Dolores Hernández; Javier López; Montserrat Rovira; Santiago Jiménez; David Valcárcel; Vicente Belloch; Mónica Jiménez; Isidro Jarque
Journal:  Haematologica       Date:  2014-07-04       Impact factor: 9.941

10.  Prognostic value of pretransplant serum C-reactive protein in patients receiving reduced-intensity conditioning allogeneic hematopoietic stem cell transplantation.

Authors:  Wataru Yamamoto; Eriko Fujii; Kenji Matsumoto; Eri Yamamoto; Jun Aoki; Masatsugu Tanaka; Yoshiaki Ishigatsubo; Heiwa Kanamori
Journal:  Int J Hematol       Date:  2016-01-20       Impact factor: 2.490

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.